
Kristina Jenei
@kjmeetswrld
Global health/oncology @LSEHealthPolicy Access to essential medicines Recovering shift #nurse Views mine
ID: 3322987117
21-08-2015 23:32:39
1,1K Tweet
1,1K Followers
902 Following

👏"This year is one of the most important years for NCDs." - richard horton, Chief Editor of The Lancet, welcoming participants at our session co-hosted with World Heart Federation at #WorldHeartSummit today. "We need solidarity, hope and a plan"



"The worst thing that the rich ever did to the poor was not to take our houses, or not to take our money, but to make us as selfish as they are." #WesternWorld #Inequality Gary Stevenson Institute of Art and Ideas youtu.be/krn-gCXO7Ok?si…

Huge news. New version of ESMO-MCBS is out! Introducing ESMO-MCBS v 2.0 with 13 new updates! Check it out today. Congratulations to the ESMO - Eur. Oncology -MCBS working group for the continued efforts to improve the tool and make it relevant and more valid. annalsofoncology.org/article/S0923-…



Evidence from a large survey of #medicine #price and #quality in #Indonesia challenges the common assumption that quality-assured medicines are necessarily more expensive Elizabeth Pisani gh.bmj.com/content/10/5/e…




We need #controlled #medicines for #pain, #mentalillness, substance use disorders.. but #access is uneven globally. A World Health Organization (WHO) rapid communication outlines its forthcoming guideline on balanced national #policies, a critical step toward #UHC Belgium UN Geneva who.int/news/item/26-0…



Outstanding work by Chris Booth and colleagues - major impact - and showing just what non pharmaceutical interventions can actually achieve!! World Health Organization (WHO) ASCO ESMO - Eur. Oncology



WHO Delays Falsified Medicine Mechanism Reform Amid Health Crisis One in 10 medicines in low- and middle-income countries are substandard or falsified, World Health Organization (WHO) estimates kills over one million people globally each year. ✍️Maayan Jaffe-Hoffman & Stefan Anderson healthpolicy-watch.news/who-delays-fal…



Most viewed this week from JAMA Oncology: While phase 3 oncology trials frequently report success based on alternative endpoints, actual enhancements in overall survival and quality of life are uncommon. ja.ma/4jyRiED
